Product Information
GS IBUPROFEN PM CAPLET is a generic product labeled by L. Perrigo Company, priced at $0.1307 per EA under NDC 00113005058. Its NADAC has been published 671 times since Nov 28, 2013.
FDA first approved this application on Dec 22, 2008.
Strength
38; 200 mg/1; mg/1
Manufacturer
L. Perrigo CompanyNDC
00113005058
Classification
Generic
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
DIPHENHYDRAMINE CITRATE; IBUPROFENApproval Type
Generic (ANDA)
FDA Application
ANDA079113FDA Approved
12/22/2008
On Market Since
3/5/2009
Pharmacological Classes
Price Statistics
The NADAC for GS IBUPROFEN PM CAPLET has been published 671 times since Nov 28, 2013, and over the history we have for it it has held within roughly two percent of its current level. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.1307 per EA |
|---|---|
| All-time high | $0.1363 (May 13, 2015) |
| All-time low | $0.1113 (Dec 22, 2021) |
| 52-week high | $0.1313 |
| 52-week low | $0.1249 |
| Median price | $0.1214 |
| Average price | $0.1224 |
| Largest weekly change | +14.2% (Jul 19, 2023) |
| Weeks tracked | 671 |
| Tracking since | Nov 28, 2013 |
Generic Alternatives
The matcher finds 4 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 4% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
L. Perrigo Company manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
diphenhydramine citrate, ibuprofen market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Histamine-1 Receptor Antagonist class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of GS IBUPROFEN PM CAPLET?
The current National Average Drug Acquisition Cost (NADAC) for GS IBUPROFEN PM CAPLET, manufactured by L. Perrigo Company, is $0.1307 per EA (NDC 00113005058), effective Sep 30, 2026.
How has the price of GS IBUPROFEN PM CAPLET changed over time?
Over the history we have for it, the NADAC for GS IBUPROFEN PM CAPLET has held within roughly two percent of its current level. It has been tracked across 671 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for GS IBUPROFEN PM CAPLET?
Since Nov 28, 2013, the NADAC for GS IBUPROFEN PM CAPLET has ranged from a low of $0.1113 (Dec 22, 2021) to a high of $0.1363 (May 13, 2015), with a median of $0.1214 per EA.
Are there cheaper alternatives to GS IBUPROFEN PM CAPLET?
Yes. 4 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, IBUPROFEN PM CAPLET, is $0.1250 per EA — about 4% below GS IBUPROFEN PM CAPLET.
Who manufactures GS IBUPROFEN PM CAPLET?
GS IBUPROFEN PM CAPLET (NDC 00113005058) is labeled by L. Perrigo Company, and CMS classifies it as a generic product.